Sorafenib Outcomes Unaffected by Age
The magnitude of improvement in progression-free survival was similar in patients younger than 65 years of age (23.9 weeks for sorafenib versus 12 weeks for placebo) and patients aged 65 years and older (25.9 weeks for sorafenib versus 11.9 weeks for placebo). “Thus, sorafenib doubled progression-free survival compared with placebo in older and younger patients,” said investigator Tim Eisen, PhD, FRCP, professor of medical oncology at
Drug-related adverse events, such as rash and desquamation, diarrhea, hand-foot skin reaction, alopecia, fatigue, and pruritus, occurred with similar frequency in the two age groups.
Overall, the findings support the use of sorafenib in older patients with advanced RCC, Dr. Eisen said.